INT47994

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 1995
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 45
Total Number 46
Disease Relevance 27.19
Pain Relevance 7.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (Lipg) extracellular space (Lipg) extracellular region (Lipg)
lipid metabolic process (Lipg)
Anatomy Link Frequency
fat 10
adipocytes 4
soleus 2
muscles 1
skeletal muscle 1
Lipg (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 428 99.92 Very High Very High Very High
antagonist 114 99.86 Very High Very High Very High
Endocannabinoid 142 99.50 Very High Very High Very High
Pain 32 99.50 Very High Very High Very High
Analgesic 12 99.50 Very High Very High Very High
Catecholamine 9 99.38 Very High Very High Very High
monoamine 5 98.64 Very High Very High Very High
fluoxetine 25 97.12 Very High Very High Very High
noradrenaline 14 95.76 Very High Very High Very High
Cannabinoid 105 95.72 Very High Very High Very High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 392 100.00 Very High Very High Very High
INFLAMMATION 499 99.92 Very High Very High Very High
Obesity 1092 99.52 Very High Very High Very High
Toxicity 44 99.52 Very High Very High Very High
Hypertrophy 34 99.48 Very High Very High Very High
Htlv Types I And Ii 2 99.32 Very High Very High Very High
Diabetes Mellitus 428 99.18 Very High Very High Very High
Weight Loss 31 98.92 Very High Very High Very High
Hyperlipidemia 89 98.82 Very High Very High Very High
Body Weight 213 98.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption.
Negative_regulation (inhibitor) of lipase in fat
1) Confidence 0.50 Published 2000 Journal Expert Opin Pharmacother Section Abstract Doc Link 11249520 Disease Relevance 0.81 Pain Relevance 0
Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers.
Negative_regulation (inhibitor) of lipase associated with fluoxetine
2) Confidence 0.42 Published 2003 Journal J Clin Pharmacol Section Title Doc Link 12723464 Disease Relevance 0.08 Pain Relevance 0.35
The aim of prospective study was to investigate the effectiveness of MEDL by evaluating the clinical outcomes with patient-oriented scoring systems.
Spec (investigate) Negative_regulation (effectiveness) of MEDL
3) Confidence 0.37 Published 2009 Journal Eur Spine J Section Abstract Doc Link 19238459 Disease Relevance 0.48 Pain Relevance 0.20
It has been reported that a pancreatic lipase inhibitor, orlistat prevented obesity and hyperlipidemia through the enhancement of fat excretion in feces and the inhibition of pancreatic lipase [23].
Negative_regulation (inhibition) of lipase in fat associated with obesity and hyperlipidemia
4) Confidence 0.31 Published 2005 Journal BMC Complement Altern Med Section Body Doc Link PMC1097713 Disease Relevance 1.01 Pain Relevance 0
Orlistat is a potent inhibitor of pancreatic lipase; therefore, the absorption of dietary fat from small intestine was strongly inhibited by feeding high-fat diet containing 0.025% orlistat (Table 2).
Negative_regulation (inhibitor) of lipase in fat
5) Confidence 0.31 Published 2005 Journal BMC Complement Altern Med Section Body Doc Link PMC1097713 Disease Relevance 0.51 Pain Relevance 0
Therefore, the application of pancreatic lipase inhibitor was examined earlier as a treatment for high-fat diet-induced obesity in humans.
Negative_regulation (inhibitor) of lipase in fat associated with obesity
6) Confidence 0.26 Published 2005 Journal BMC Complement Altern Med Section Body Doc Link PMC1097713 Disease Relevance 1.18 Pain Relevance 0
It has been reported that a pancreatic lipase inhibitor, orlistat prevented obesity and hyperlipidemia through the enhancement of fat excretion in feces and the inhibition of pancreatic lipase [23].
Negative_regulation (inhibitor) of lipase in fat associated with obesity and hyperlipidemia
7) Confidence 0.26 Published 2005 Journal BMC Complement Altern Med Section Body Doc Link PMC1097713 Disease Relevance 1.09 Pain Relevance 0
The anti-obesity effects of chikusetsusaponins isolated from P. japonicus rhizomes in mice fed a high-fat diet may be partly mediated through delaying the intestinal absorption of dietary fat by inhibiting pancreatic lipase activity.
Negative_regulation (inhibiting) of lipase in fat associated with obesity
8) Confidence 0.26 Published 2005 Journal BMC Complement Altern Med Section Abstract Doc Link PMC1097713 Disease Relevance 0.40 Pain Relevance 0
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system.
Negative_regulation (blockade) of lipase associated with endocannabinoid and analgesic
9) Confidence 0.24 Published 2010 Journal Nat. Neurosci. Section Title Doc Link 20729846 Disease Relevance 0.07 Pain Relevance 1.36
We found that a similar form of functional antagonism was produced by sustained inactivation of monoacylglycerol lipase (MAGL), the principal degradative enzyme for the endocannabinoid 2-arachidonoylglycerol.
Negative_regulation (inactivation) of lipase associated with endocannabinoid
10) Confidence 0.24 Published 2010 Journal Nat. Neurosci. Section Abstract Doc Link 20729846 Disease Relevance 0.07 Pain Relevance 0.65
In fact, total chikusetsusaponins strongly inhibited the pancreatic lipase activity, and therefore, we attempted to isolate substance(s) from total saponins that inhibit pancreatic lipase activity.
Negative_regulation (inhibited) of lipase
11) Confidence 0.23 Published 2005 Journal BMC Complement Altern Med Section Body Doc Link PMC1097713 Disease Relevance 0.30 Pain Relevance 0.05
Total chikusetsusaponins, chikusetsusaponin III, 28-deglucosyl-chikusetsusaponin IV and 28-deglucosyl-chikusetsusaponin V inhibited the pancreatic lipase activity.


Negative_regulation (inhibited) of lipase
12) Confidence 0.23 Published 2005 Journal BMC Complement Altern Med Section Abstract Doc Link PMC1097713 Disease Relevance 0.40 Pain Relevance 0
Consequently, it is suggested that their metabolites (28-deglucosyl form) exhibit the inhibition of pancreatic lipase activity.


Negative_regulation (inhibition) of lipase
13) Confidence 0.23 Published 2005 Journal BMC Complement Altern Med Section Body Doc Link PMC1097713 Disease Relevance 0.24 Pain Relevance 0
This finding suggests that feeding level of 0.024% orlistat in the high-fat diet to mice for a long term may cause the physiological toxicity through the continuous inhibition of pancreatic lipase.
Negative_regulation (inhibition) of lipase in fat associated with toxicity
14) Confidence 0.23 Published 2005 Journal BMC Complement Altern Med Section Body Doc Link PMC1097713 Disease Relevance 0.74 Pain Relevance 0
Orlistat (a lipase inhibitor) was purchased from Hong Kong Market.
Negative_regulation (inhibitor) of lipase
15) Confidence 0.23 Published 2005 Journal BMC Complement Altern Med Section Body Doc Link PMC1097713 Disease Relevance 0.62 Pain Relevance 0
Total chikusetsusaponins isolated from P. japonicus may prevent high-fat-diet-induced increases in body weight and fat storage in adipose tissue by inhibiting intestinal absorption of dietary fat through the inhibition of pancreatic lipase activity, and the active components were identified here as chikusetsusaponins III and IV, 28-deglucosyl-chikusetsusaponins IV and V.
Negative_regulation (inhibition) of lipase in fat associated with body weight and obesity
16) Confidence 0.23 Published 2005 Journal BMC Complement Altern Med Section Body Doc Link PMC1097713 Disease Relevance 0.41 Pain Relevance 0
For in vitro experiments, the inhibitory effects of total chikusetsusaponins and various purified chikusetsusaponins on pancreatic lipase activity were determined by measuring the rate of release of oleic acid from triolein in an assay system using triolein emulsified with lecithin.


Negative_regulation (effects) of lipase
17) Confidence 0.23 Published 2005 Journal BMC Complement Altern Med Section Abstract Doc Link PMC1097713 Disease Relevance 0.82 Pain Relevance 0
We observed that ghrelin inhibits the excitatory input on PVN neurons and this effect is blocked by the co-administration of the DAG lipase inhibitor, THL or CB1 antagonist, AM251, suggesting that 2-AG synthesis and functional CB1 is required for ghrelin to result in this effect.
Negative_regulation (inhibitor) of lipase in neurons associated with antagonist
18) Confidence 0.14 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2258435 Disease Relevance 0 Pain Relevance 0.33
In this study we demonstrate that IIA fibers also undergo hypertrophy in response to myostatin inhibition in the soleus and EDL.
Negative_regulation (inhibition) of EDL in soleus associated with hypertrophy
19) Confidence 0.12 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2820101 Disease Relevance 0.45 Pain Relevance 0
The basal lipolysis rates decreased by about 50% after weight reduction and the maximum enzyme activity of hormone-sensitive lipase was also reduced by almost 50%. 4.
Negative_regulation (reduced) of lipase associated with weight loss
20) Confidence 0.11 Published 1995 Journal Clin. Sci. Section Abstract Doc Link 7493443 Disease Relevance 0.98 Pain Relevance 0.37

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox